The team’s work has led to the discovery of an advanced preclinical candidate. Now, Cioffi and Petruhkin have received a $6.4 million grant over five years from the National Institutes of Heath’s National Eye Institute to conduct drug development work and investigational new drug (IND)-enabling toxicology studies.
Menu
Menu
